BAVENO, Italy, June 30, 2014 /PRNewswire/ -- GrowBLOX™
Sciences, Inc. (OTCQB: GBLX) is represented at the 24th Annual
International Cannabinoid Research Society Symposium on the
Cannabinoids (ICRS 2014) by their Chief Science Officer and Member
of the International Cannabinoid Research Society, Andrea L. Small-Howard, PhD, MBA. GBLX seeks
co-development partners from ICRS 2014 to assist in their pursuit
of the research, testing, and development of FDA-approved
cannabinoid treatment options using the stable profile of
phytocannabinoids present in the cannabis plant cultivated in their
proprietary GrowBLOX™ controlled indoor growing
system.
ICRS 2014 provides an international forum where the brightest
minds in cannabinoid research exchange scientific information on
the latest developments in their field. The conference, which is
sponsored by GW Pharmaceuticals and other cannabinoid business
leaders, also promotes dialogue regarding where cannabinoid
therapies are headed in the context of the international political
and regulatory environments.
"GBLX is eager to forge solid relationships in the international
cannabinoid research and business communities that will facilitate
our goal of nurturing a cannabis-based biopharmaceutical pipeline,"
explains Andrea Small-Howard, CSO
and Board Member of GBLX.
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc., is a research and biotechnical company
that has developed proprietary indoor growing chambers specifically
designed for medical cannabis cultivation. The GrowBLOX™
chamber allows for completely controlled growing conditions,
ensuring the manufacture of a consistent, toxin-free, natural and
medicinal-grade product. The Company believes that the
advantages of a controlled environment over traditional outdoor or
greenhouse growing, will empower the public, nutraceutical and
pharmaceutical industries to embrace cannabis as an effective
treatment for a myriad of serious medical conditions. More
recently, the Company endeavors to pursue the research,
testing, and development of FDA-approved treatment options using
the phytocannabinoids extracted from cannabis grown in its GrowBLOX
chamber. http://www.gbsciences.com
Forward-Looking Statements
Except for historical information contained herein, the statements
in this release are forward-looking and made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are inherently unreliable
and actual results may differ materially. Examples of
forward-looking statements in this news release include statements
regarding the payment of dividends, marketing and distribution
plans, development activities and anticipated operating
results. Factors which could cause actual results to differ
materially from these forward-looking statements include such
factors as the Company's ability to accomplish its business
initiatives, significant fluctuations in marketing expenses and
ability to achieve and expand significant levels of revenues, or
recognize net income, from the sale of its products and services,
as well as the introduction of competing products, or management's
ability to attract and maintain qualified personnel necessary for
the development and commercialization of its planned products, and
other information that may be detailed from time to time in the
Company's filings with the United States Securities and Exchange
Commission. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact:
Jonathan Barkman
Riverview Capital Enterprises
+1-866-845-0105
SOURCE GrowBLOX Sciences, Inc.